Perrone and colleagues described a significant impact on response and PFS by PIK3CA/PTEN mutations in a small study of 32 patients[12], and Sartori-Bianchi et al presented a significant PFS and OS survival benefit in non-mutated tumours, and suggested that these mutations may be a rational supplement to KRAS mutational testing with potential for clinical application[13]. This evidence concerns the gene PIK3CA and neoplasm.